COVID-19 Impact on Global Neurological Biomarkers Market

1. Global Neurological Biomarkers Market - Forecast to 2026 The findings reviewed by GME stated that the Global Neurological Biomarkers Market would grow at a CAGR value of 10.2 percent from 2021 to 2026. Today, with advancing technology and neurological applications, the awareness about the effectiveness of biomarker signature in diagnosing diseases or disorders is also increasing. Besides the beneficial features attributed to the neurological biomarkers, the annual exponential increase in the rate of neurological diseases is also accelerating growth in the market. Browse 159 Market Data Tables and 119 Figures spread through 189 Pages and in-depth TOC on “Global Neurological Biomarkers Market - Forecast to 2026”. https://www.globalmarketestimates.com/market-report/global-neurological-biomarkers-market-3181 By Application(Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Autism Spectrum Disorders, and Others), By Type (Genomic, Proteomic, Metabolomic, Imaging, and Others), By End-User (Hospital Laboratories, Independent Clinical Diagnostic Centers, Research Organizations, and Others), By Region (North America, Europe, Asia Pacific, MEA, and CSA);Competitive Landscape, Company Market Share Analysis, and Competitor Analysis Key Market Insights Alzheimer's disease is analyzed to hold predominance in the market due to the rise in populaces of geriatric population. Genomic type is substantially used to identify and diagnose biomarkers and subsequently identify various diseases and disorders, thus holding the market's largest share. Hospital laboratories hold the largest share and have their dominance in the market because they are a part of more outstanding medical infrastructure and investment. North America has a significant revenue proportion in the neurological biomarkers industry due to the presence of several leading major players in this area. Acumen Pharmaceuticals, Abbott, Banyan Biomarkers, Inc., Athena Diagnostics, QIAGEN, AbaStarMDx, Inc., Alseres Pharmaceuticals, Inc., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., and Myriad RBM, Inc. are few prominent competitors in the market. Browse the Report @ https://www.globalmarketestimates.com/market-report/global-neurological- biomarkers-market-3181 Application Outlook (Revenue, USD Billion, 2021-2026) Alzheimer’s Disease

2. Parkinson’s Disease Multiple Sclerosis Autism Spectrum Disorders Others Type Outlook (Revenue, USD Billion, 2021-2026) Genomic Proteomic Metabolomic Imaging Others End-UserOutlook (Revenue, USD Billion, 2021-2026) Hospital Laboratories Independent Clinical Diagnostic Centers Research Organizations Others Regional Outlook (Revenue, USD Billion, 2021-2026) North America The US. Canada Mexico Europe Germany UK France Spain Italy Rest of Europe

3. Asia Pacific China India Japan South Korea Australia Rest of APAC Central & South America Brazil Argentina Rest of CSA Middle East & Africa Saudi Arabia UAE Rest of MEA Contact: Tracy Simon Email address: tracy.simon@globalmarketestimates.com Phone Number: +16026667238 Website: https://www.globalmarketestimates.com/ Check our Latest Blogs: https://www.globalmarketestimates.com/blog-posts.php